NCT03357575

Brief Summary

The aim of this study was to evaluate the efficacy and safety of Mesenchymal Stem Cells (MSCs) from adipose anticular injection in comparison with hyaluronic acid anticular injection in the treatment of human knee osteoarthritis(OA).

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
14

participants targeted

Target at below P25 for not_applicable knee-osteoarthritis

Timeline
Completed

Started Jan 2018

Longer than P75 for not_applicable knee-osteoarthritis

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 25, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 30, 2017

Completed
1 month until next milestone

Study Start

First participant enrolled

January 1, 2018

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2020

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

November 30, 2017

Status Verified

November 1, 2017

Enrollment Period

2.4 years

First QC Date

November 25, 2017

Last Update Submit

November 29, 2017

Conditions

Keywords

Knee Osteoarthritisadiposemesenchymal stem cells

Outcome Measures

Primary Outcomes (1)

  • Unexplained local and systemic symptoms or death

    The severity of AE must be recorded and graded according to the CTCAE criteria, and its relationship to therapy must be assessed according to the following definition:①not related: there is evidence that the cause of adverse events is not due to intra-articular injection therapy (such as previous conditions, potential diseases, concurrent diseases); ②related: AE and intra-articular injection are time-related and it is known or suspected that intra-articular injection of drugs can cause the AE; ③it can't be assessed.

    2 years

Secondary Outcomes (2)

  • VAS score

    2 years

  • WOMAC score

    2 years

Study Arms (2)

Mesenchymal Stem Cells from adipose

EXPERIMENTAL

Mesenchymal Stem Cells from adipose will be injected.

Biological: Mesenchymal Stem Cells from adipose

hyaluronic acid

ACTIVE COMPARATOR

Hyaluronic acid will be injectied.

Biological: Hyaluronic Acid

Interventions

inject mesenchymal Stem Cells from adipose

Mesenchymal Stem Cells from adipose
Hyaluronic AcidBIOLOGICAL

inject hyaluronic acid

hyaluronic acid

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • K / L score of 2-3;
  • chronic knee pain;
  • no local or systemic infection;
  • without obvious contraindication of the joint puncture from hematology and biochemical tests;
  • informed consent.

You may not qualify if:

  • older than 75 years old or less than 18 years old, or without full capacity for civil conduct;
  • HIV, hepatitis virus or syphilis virus infection or their serology is positive;
  • BMI index is greater than 30;
  • congenital or acquired knee deformity;
  • pregnant or lactating women;
  • tumor patients;
  • immunodeficiency patients;
  • intra-articular drug injection history within 3 months;
  • participating in other clinical trials;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Osteoarthritis, Knee

Interventions

Hyaluronic Acid

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

GlycosaminoglycansPolysaccharidesCarbohydrates

Study Officials

  • Ziyi Yang

    arthritis clinic and research center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
arthritis clinic and research center

Study Record Dates

First Submitted

November 25, 2017

First Posted

November 30, 2017

Study Start

January 1, 2018

Primary Completion

June 1, 2020

Study Completion

December 1, 2020

Last Updated

November 30, 2017

Record last verified: 2017-11

Data Sharing

IPD Sharing
Will not share